nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.201	0.601	CbGbCtD
Treprostinil—CYP2C9—Progesterone—uterine cancer	0.133	0.398	CbGbCtD
Treprostinil—P2RY12—artery—uterine cancer	0.0401	0.204	CbGeAlD
Treprostinil—PTGIR—artery—uterine cancer	0.0256	0.13	CbGeAlD
Treprostinil—P2RY12—epithelium—uterine cancer	0.0152	0.0773	CbGeAlD
Treprostinil—PPARD—uterine cervix—uterine cancer	0.0125	0.0636	CbGeAlD
Treprostinil—PPARD—decidua—uterine cancer	0.0119	0.0606	CbGeAlD
Treprostinil—PPARD—mammalian vulva—uterine cancer	0.011	0.0557	CbGeAlD
Treprostinil—PTGIR—epithelium—uterine cancer	0.0097	0.0493	CbGeAlD
Treprostinil—PPARD—female reproductive system—uterine cancer	0.00938	0.0477	CbGeAlD
Treprostinil—PTGIR—smooth muscle tissue—uterine cancer	0.00935	0.0475	CbGeAlD
Treprostinil—PTGIR—renal system—uterine cancer	0.009	0.0457	CbGeAlD
Treprostinil—PPARD—female gonad—uterine cancer	0.00854	0.0434	CbGeAlD
Treprostinil—PPARD—vagina—uterine cancer	0.00849	0.0431	CbGeAlD
Treprostinil—PTGIR—female reproductive system—uterine cancer	0.00721	0.0366	CbGeAlD
Treprostinil—PTGIR—female gonad—uterine cancer	0.00656	0.0333	CbGeAlD
Treprostinil—PPARD—lymph node—uterine cancer	0.00549	0.0279	CbGeAlD
Treprostinil—PTGIR—lymph node—uterine cancer	0.00422	0.0214	CbGeAlD
Treprostinil—PTGIR—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00328	0.0638	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptors—PGR—uterine cancer	0.00274	0.0534	CbGpPWpGaD
Treprostinil—CYP2C9—female reproductive system—uterine cancer	0.00258	0.0131	CbGeAlD
Treprostinil—PPARD—Nuclear Receptors—ESR2—uterine cancer	0.00241	0.047	CbGpPWpGaD
Treprostinil—PPARD—The citric acid (TCA) cycle and respiratory electron transport—NDUFB11—uterine cancer	0.00233	0.0454	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00217	0.0422	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00191	0.0371	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptors—ESR1—uterine cancer	0.00146	0.0285	CbGpPWpGaD
Treprostinil—Dyspnoea—Progesterone—uterine cancer	0.00142	0.00341	CcSEcCtD
Treprostinil—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00142	0.00341	CcSEcCtD
Treprostinil—Viral infection—Epirubicin—uterine cancer	0.00142	0.00341	CcSEcCtD
Treprostinil—Rectal haemorrhage—Epirubicin—uterine cancer	0.00142	0.00341	CcSEcCtD
Treprostinil—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00142	0.0034	CcSEcCtD
Treprostinil—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.00338	CcSEcCtD
Treprostinil—Cellulitis—Epirubicin—uterine cancer	0.00141	0.00338	CcSEcCtD
Treprostinil—Dyspepsia—Progesterone—uterine cancer	0.00141	0.00337	CcSEcCtD
Treprostinil—Decreased appetite—Progesterone—uterine cancer	0.00139	0.00333	CcSEcCtD
Treprostinil—Erythema—Dactinomycin—uterine cancer	0.00138	0.00331	CcSEcCtD
Treprostinil—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00138	0.00331	CcSEcCtD
Treprostinil—Fatigue—Progesterone—uterine cancer	0.00138	0.0033	CcSEcCtD
Treprostinil—Pain—Progesterone—uterine cancer	0.00137	0.00327	CcSEcCtD
Treprostinil—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00135	0.00324	CcSEcCtD
Treprostinil—Bone pain—Epirubicin—uterine cancer	0.00134	0.00321	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00316	CcSEcCtD
Treprostinil—Feeling abnormal—Progesterone—uterine cancer	0.00132	0.00315	CcSEcCtD
Treprostinil—Rectal haemorrhage—Doxorubicin—uterine cancer	0.00131	0.00315	CcSEcCtD
Treprostinil—Viral infection—Doxorubicin—uterine cancer	0.00131	0.00315	CcSEcCtD
Treprostinil—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00314	CcSEcCtD
Treprostinil—Cellulitis—Doxorubicin—uterine cancer	0.00131	0.00313	CcSEcCtD
Treprostinil—Gastrointestinal pain—Progesterone—uterine cancer	0.00131	0.00313	CcSEcCtD
Treprostinil—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00311	CcSEcCtD
Treprostinil—Neck pain—Epirubicin—uterine cancer	0.0013	0.00311	CcSEcCtD
Treprostinil—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00309	CcSEcCtD
Treprostinil—Pneumonia—Etoposide—uterine cancer	0.00129	0.00309	CcSEcCtD
Treprostinil—Pulmonary embolism—Epirubicin—uterine cancer	0.00128	0.00308	CcSEcCtD
Treprostinil—Ill-defined disorder—Dactinomycin—uterine cancer	0.00128	0.00308	CcSEcCtD
Treprostinil—Anaemia—Dactinomycin—uterine cancer	0.00128	0.00306	CcSEcCtD
Treprostinil—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00127	0.00305	CcSEcCtD
Treprostinil—Abdominal pain—Progesterone—uterine cancer	0.00126	0.00303	CcSEcCtD
Treprostinil—Body temperature increased—Progesterone—uterine cancer	0.00126	0.00303	CcSEcCtD
Treprostinil—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.00301	CcSEcCtD
Treprostinil—Melaena—Epirubicin—uterine cancer	0.00125	0.003	CcSEcCtD
Treprostinil—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00125	0.00299	CcSEcCtD
Treprostinil—Malaise—Dactinomycin—uterine cancer	0.00125	0.00299	CcSEcCtD
Treprostinil—Bone pain—Doxorubicin—uterine cancer	0.00124	0.00297	CcSEcCtD
Treprostinil—Neck pain—Doxorubicin—uterine cancer	0.0012	0.00288	CcSEcCtD
Treprostinil—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00119	0.00286	CcSEcCtD
Treprostinil—Pulmonary embolism—Doxorubicin—uterine cancer	0.00119	0.00285	CcSEcCtD
Treprostinil—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00284	CcSEcCtD
Treprostinil—Cramps of lower extremities—Epirubicin—uterine cancer	0.00118	0.00283	CcSEcCtD
Treprostinil—Myalgia—Dactinomycin—uterine cancer	0.00118	0.00282	CcSEcCtD
Treprostinil—Discomfort—Dactinomycin—uterine cancer	0.00116	0.00279	CcSEcCtD
Treprostinil—Ecchymosis—Epirubicin—uterine cancer	0.00116	0.00278	CcSEcCtD
Treprostinil—Melaena—Doxorubicin—uterine cancer	0.00116	0.00278	CcSEcCtD
Treprostinil—PPARD—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00116	0.0225	CbGpPWpGaD
Treprostinil—Asthenia—Progesterone—uterine cancer	0.00115	0.00275	CcSEcCtD
Treprostinil—PPARD—NRF2 pathway—NFE2L2—uterine cancer	0.00115	0.0223	CbGpPWpGaD
Treprostinil—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00274	CcSEcCtD
Treprostinil—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00274	CcSEcCtD
Treprostinil—Pruritus—Progesterone—uterine cancer	0.00113	0.00271	CcSEcCtD
Treprostinil—Oedema—Dactinomycin—uterine cancer	0.00113	0.00271	CcSEcCtD
Treprostinil—Infection—Dactinomycin—uterine cancer	0.00112	0.00269	CcSEcCtD
Treprostinil—Sepsis—Epirubicin—uterine cancer	0.00111	0.00267	CcSEcCtD
Treprostinil—Thrombocytopenia—Dactinomycin—uterine cancer	0.0011	0.00265	CcSEcCtD
Treprostinil—PPARD—NRF2 pathway—GPX3—uterine cancer	0.00109	0.0213	CbGpPWpGaD
Treprostinil—Diarrhoea—Progesterone—uterine cancer	0.00109	0.00262	CcSEcCtD
Treprostinil—Cramps of lower extremities—Doxorubicin—uterine cancer	0.00109	0.00261	CcSEcCtD
Treprostinil—Thrombophlebitis—Epirubicin—uterine cancer	0.00108	0.00258	CcSEcCtD
Treprostinil—Anorexia—Dactinomycin—uterine cancer	0.00108	0.00258	CcSEcCtD
Treprostinil—Ecchymosis—Doxorubicin—uterine cancer	0.00107	0.00257	CcSEcCtD
Treprostinil—Flushing—Etoposide—uterine cancer	0.00107	0.00256	CcSEcCtD
Treprostinil—Dizziness—Progesterone—uterine cancer	0.00106	0.00253	CcSEcCtD
Treprostinil—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00249	CcSEcCtD
Treprostinil—Sepsis—Doxorubicin—uterine cancer	0.00103	0.00247	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00103	0.00246	CcSEcCtD
Treprostinil—Cardiac failure congestive—Epirubicin—uterine cancer	0.00103	0.00246	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—HMGA1—uterine cancer	0.00102	0.0199	CbGpPWpGaD
Treprostinil—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00102	0.00245	CcSEcCtD
Treprostinil—Vomiting—Progesterone—uterine cancer	0.00102	0.00243	CcSEcCtD
Treprostinil—Rash—Progesterone—uterine cancer	0.00101	0.00241	CcSEcCtD
Treprostinil—Dermatitis—Progesterone—uterine cancer	0.00101	0.00241	CcSEcCtD
Treprostinil—Headache—Progesterone—uterine cancer	0.001	0.0024	CcSEcCtD
Treprostinil—Thrombophlebitis—Doxorubicin—uterine cancer	0.000996	0.00239	CcSEcCtD
Treprostinil—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00099	0.00237	CcSEcCtD
Treprostinil—Decreased appetite—Dactinomycin—uterine cancer	0.000981	0.00235	CcSEcCtD
Treprostinil—Fatigue—Dactinomycin—uterine cancer	0.000973	0.00233	CcSEcCtD
Treprostinil—Back pain—Etoposide—uterine cancer	0.000968	0.00232	CcSEcCtD
Treprostinil—Pain—Dactinomycin—uterine cancer	0.000965	0.00231	CcSEcCtD
Treprostinil—Muscle spasms—Etoposide—uterine cancer	0.000962	0.00231	CcSEcCtD
Treprostinil—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000957	0.00229	CcSEcCtD
Treprostinil—Cardiac failure—Epirubicin—uterine cancer	0.000954	0.00229	CcSEcCtD
Treprostinil—Cardiac failure congestive—Doxorubicin—uterine cancer	0.00095	0.00228	CcSEcCtD
Treprostinil—Nausea—Progesterone—uterine cancer	0.000948	0.00227	CcSEcCtD
Treprostinil—Pain in extremity—Epirubicin—uterine cancer	0.000931	0.00223	CcSEcCtD
Treprostinil—Feeling abnormal—Dactinomycin—uterine cancer	0.00093	0.00223	CcSEcCtD
Treprostinil—Ill-defined disorder—Etoposide—uterine cancer	0.000928	0.00223	CcSEcCtD
Treprostinil—Anaemia—Etoposide—uterine cancer	0.000925	0.00222	CcSEcCtD
Treprostinil—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000923	0.00221	CcSEcCtD
Treprostinil—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00092	0.00221	CcSEcCtD
Treprostinil—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000912	0.00219	CcSEcCtD
Treprostinil—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000911	0.00218	CcSEcCtD
Treprostinil—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000906	0.00217	CcSEcCtD
Treprostinil—Malaise—Etoposide—uterine cancer	0.000902	0.00216	CcSEcCtD
Treprostinil—Body temperature increased—Dactinomycin—uterine cancer	0.000892	0.00214	CcSEcCtD
Treprostinil—Abdominal pain—Dactinomycin—uterine cancer	0.000892	0.00214	CcSEcCtD
Treprostinil—Cardiac failure—Doxorubicin—uterine cancer	0.000883	0.00212	CcSEcCtD
Treprostinil—Loss of consciousness—Etoposide—uterine cancer	0.000879	0.00211	CcSEcCtD
Treprostinil—Cough—Etoposide—uterine cancer	0.000873	0.00209	CcSEcCtD
Treprostinil—Dehydration—Epirubicin—uterine cancer	0.000866	0.00208	CcSEcCtD
Treprostinil—Pain in extremity—Doxorubicin—uterine cancer	0.000862	0.00207	CcSEcCtD
Treprostinil—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000859	0.00206	CcSEcCtD
Treprostinil—Chest pain—Etoposide—uterine cancer	0.000852	0.00204	CcSEcCtD
Treprostinil—Hypokalaemia—Epirubicin—uterine cancer	0.000848	0.00203	CcSEcCtD
Treprostinil—Discomfort—Etoposide—uterine cancer	0.000842	0.00202	CcSEcCtD
Treprostinil—Infection—Etoposide—uterine cancer	0.000811	0.00194	CcSEcCtD
Treprostinil—Asthenia—Dactinomycin—uterine cancer	0.00081	0.00194	CcSEcCtD
Treprostinil—PPARD—Presenilin action in Notch and Wnt signaling—CTNNB1—uterine cancer	0.000806	0.0157	CbGpPWpGaD
Treprostinil—Influenza—Epirubicin—uterine cancer	0.000805	0.00193	CcSEcCtD
Treprostinil—Dehydration—Doxorubicin—uterine cancer	0.000801	0.00192	CcSEcCtD
Treprostinil—Thrombocytopenia—Etoposide—uterine cancer	0.0008	0.00192	CcSEcCtD
Treprostinil—Tachycardia—Etoposide—uterine cancer	0.000797	0.00191	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00079	0.0154	CbGpPWpGaD
Treprostinil—Hypokalaemia—Doxorubicin—uterine cancer	0.000784	0.00188	CcSEcCtD
Treprostinil—Anorexia—Etoposide—uterine cancer	0.000778	0.00187	CcSEcCtD
Treprostinil—Bronchitis—Epirubicin—uterine cancer	0.000774	0.00186	CcSEcCtD
Treprostinil—Diarrhoea—Dactinomycin—uterine cancer	0.000772	0.00185	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—SOCS3—uterine cancer	0.000767	0.0149	CbGpPWpGaD
Treprostinil—Hypotension—Etoposide—uterine cancer	0.000763	0.00183	CcSEcCtD
Treprostinil—Influenza—Doxorubicin—uterine cancer	0.000745	0.00179	CcSEcCtD
Treprostinil—Paraesthesia—Etoposide—uterine cancer	0.000733	0.00176	CcSEcCtD
Treprostinil—Dyspnoea—Etoposide—uterine cancer	0.000728	0.00175	CcSEcCtD
Treprostinil—Pneumonia—Epirubicin—uterine cancer	0.000722	0.00173	CcSEcCtD
Treprostinil—Vomiting—Dactinomycin—uterine cancer	0.000717	0.00172	CcSEcCtD
Treprostinil—Bronchitis—Doxorubicin—uterine cancer	0.000716	0.00172	CcSEcCtD
Treprostinil—Rash—Dactinomycin—uterine cancer	0.000711	0.00171	CcSEcCtD
Treprostinil—Decreased appetite—Etoposide—uterine cancer	0.00071	0.0017	CcSEcCtD
Treprostinil—Fatigue—Etoposide—uterine cancer	0.000704	0.00169	CcSEcCtD
Treprostinil—Pain—Etoposide—uterine cancer	0.000698	0.00167	CcSEcCtD
Treprostinil—Urinary tract infection—Epirubicin—uterine cancer	0.000698	0.00167	CcSEcCtD
Treprostinil—Haematuria—Epirubicin—uterine cancer	0.000684	0.00164	CcSEcCtD
Treprostinil—Epistaxis—Epirubicin—uterine cancer	0.000677	0.00162	CcSEcCtD
Treprostinil—Sinusitis—Epirubicin—uterine cancer	0.000673	0.00161	CcSEcCtD
Treprostinil—Feeling abnormal—Etoposide—uterine cancer	0.000673	0.00161	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—SMAD3—uterine cancer	0.00067	0.0131	CbGpPWpGaD
Treprostinil—Nausea—Dactinomycin—uterine cancer	0.00067	0.00161	CcSEcCtD
Treprostinil—Pneumonia—Doxorubicin—uterine cancer	0.000668	0.0016	CcSEcCtD
Treprostinil—Gastrointestinal pain—Etoposide—uterine cancer	0.000668	0.0016	CcSEcCtD
Treprostinil—Bradycardia—Epirubicin—uterine cancer	0.000656	0.00157	CcSEcCtD
Treprostinil—Haemoglobin—Epirubicin—uterine cancer	0.000648	0.00155	CcSEcCtD
Treprostinil—Rhinitis—Epirubicin—uterine cancer	0.000646	0.00155	CcSEcCtD
Treprostinil—Body temperature increased—Etoposide—uterine cancer	0.000646	0.00155	CcSEcCtD
Treprostinil—Abdominal pain—Etoposide—uterine cancer	0.000646	0.00155	CcSEcCtD
Treprostinil—Urinary tract infection—Doxorubicin—uterine cancer	0.000646	0.00155	CcSEcCtD
Treprostinil—Haemorrhage—Epirubicin—uterine cancer	0.000644	0.00154	CcSEcCtD
Treprostinil—Pharyngitis—Epirubicin—uterine cancer	0.00064	0.00153	CcSEcCtD
Treprostinil—Oedema peripheral—Epirubicin—uterine cancer	0.000635	0.00152	CcSEcCtD
Treprostinil—Haematuria—Doxorubicin—uterine cancer	0.000633	0.00152	CcSEcCtD
Treprostinil—Epistaxis—Doxorubicin—uterine cancer	0.000626	0.0015	CcSEcCtD
Treprostinil—Sinusitis—Doxorubicin—uterine cancer	0.000623	0.00149	CcSEcCtD
Treprostinil—PPARD—Ectoderm Differentiation—FGFR2—uterine cancer	0.00061	0.0119	CbGpPWpGaD
Treprostinil—Bradycardia—Doxorubicin—uterine cancer	0.000607	0.00146	CcSEcCtD
Treprostinil—Haemoglobin—Doxorubicin—uterine cancer	0.000599	0.00144	CcSEcCtD
Treprostinil—Flushing—Epirubicin—uterine cancer	0.000598	0.00143	CcSEcCtD
Treprostinil—Rhinitis—Doxorubicin—uterine cancer	0.000598	0.00143	CcSEcCtD
Treprostinil—Haemorrhage—Doxorubicin—uterine cancer	0.000596	0.00143	CcSEcCtD
Treprostinil—Pharyngitis—Doxorubicin—uterine cancer	0.000592	0.00142	CcSEcCtD
Treprostinil—Oedema peripheral—Doxorubicin—uterine cancer	0.000587	0.00141	CcSEcCtD
Treprostinil—Asthenia—Etoposide—uterine cancer	0.000586	0.0014	CcSEcCtD
Treprostinil—Pruritus—Etoposide—uterine cancer	0.000578	0.00139	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000571	0.0111	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000571	0.0111	CbGpPWpGaD
Treprostinil—Erythema—Epirubicin—uterine cancer	0.000561	0.00134	CcSEcCtD
Treprostinil—Diarrhoea—Etoposide—uterine cancer	0.000559	0.00134	CcSEcCtD
Treprostinil—Flushing—Doxorubicin—uterine cancer	0.000553	0.00133	CcSEcCtD
Treprostinil—Tension—Epirubicin—uterine cancer	0.00055	0.00132	CcSEcCtD
Treprostinil—Nervousness—Epirubicin—uterine cancer	0.000545	0.00131	CcSEcCtD
Treprostinil—Back pain—Epirubicin—uterine cancer	0.000543	0.0013	CcSEcCtD
Treprostinil—Dizziness—Etoposide—uterine cancer	0.00054	0.00129	CcSEcCtD
Treprostinil—Muscle spasms—Epirubicin—uterine cancer	0.000539	0.00129	CcSEcCtD
Treprostinil—Ill-defined disorder—Epirubicin—uterine cancer	0.00052	0.00125	CcSEcCtD
Treprostinil—Vomiting—Etoposide—uterine cancer	0.000519	0.00124	CcSEcCtD
Treprostinil—Erythema—Doxorubicin—uterine cancer	0.000519	0.00124	CcSEcCtD
Treprostinil—Anaemia—Epirubicin—uterine cancer	0.000518	0.00124	CcSEcCtD
Treprostinil—Rash—Etoposide—uterine cancer	0.000515	0.00123	CcSEcCtD
Treprostinil—Dermatitis—Etoposide—uterine cancer	0.000514	0.00123	CcSEcCtD
Treprostinil—Headache—Etoposide—uterine cancer	0.000512	0.00123	CcSEcCtD
Treprostinil—Tension—Doxorubicin—uterine cancer	0.000509	0.00122	CcSEcCtD
Treprostinil—PPARD—Gene Expression—PHF1—uterine cancer	0.000508	0.00988	CbGpPWpGaD
Treprostinil—Malaise—Epirubicin—uterine cancer	0.000506	0.00121	CcSEcCtD
Treprostinil—Nervousness—Doxorubicin—uterine cancer	0.000504	0.00121	CcSEcCtD
Treprostinil—Syncope—Epirubicin—uterine cancer	0.000503	0.00121	CcSEcCtD
Treprostinil—Back pain—Doxorubicin—uterine cancer	0.000502	0.0012	CcSEcCtD
Treprostinil—Muscle spasms—Doxorubicin—uterine cancer	0.000499	0.0012	CcSEcCtD
Treprostinil—Palpitations—Epirubicin—uterine cancer	0.000496	0.00119	CcSEcCtD
Treprostinil—Loss of consciousness—Epirubicin—uterine cancer	0.000493	0.00118	CcSEcCtD
Treprostinil—Cough—Epirubicin—uterine cancer	0.000489	0.00117	CcSEcCtD
Treprostinil—Nausea—Etoposide—uterine cancer	0.000485	0.00116	CcSEcCtD
Treprostinil—Ill-defined disorder—Doxorubicin—uterine cancer	0.000482	0.00115	CcSEcCtD
Treprostinil—Anaemia—Doxorubicin—uterine cancer	0.00048	0.00115	CcSEcCtD
Treprostinil—Myalgia—Epirubicin—uterine cancer	0.000478	0.00114	CcSEcCtD
Treprostinil—Arthralgia—Epirubicin—uterine cancer	0.000478	0.00114	CcSEcCtD
Treprostinil—Chest pain—Epirubicin—uterine cancer	0.000478	0.00114	CcSEcCtD
Treprostinil—Anxiety—Epirubicin—uterine cancer	0.000476	0.00114	CcSEcCtD
Treprostinil—Discomfort—Epirubicin—uterine cancer	0.000472	0.00113	CcSEcCtD
Treprostinil—Malaise—Doxorubicin—uterine cancer	0.000468	0.00112	CcSEcCtD
Treprostinil—Syncope—Doxorubicin—uterine cancer	0.000465	0.00112	CcSEcCtD
Treprostinil—PPARD—Ectoderm Differentiation—CCL2—uterine cancer	0.000459	0.00894	CbGpPWpGaD
Treprostinil—Palpitations—Doxorubicin—uterine cancer	0.000459	0.0011	CcSEcCtD
Treprostinil—Oedema—Epirubicin—uterine cancer	0.000458	0.0011	CcSEcCtD
Treprostinil—Loss of consciousness—Doxorubicin—uterine cancer	0.000456	0.00109	CcSEcCtD
Treprostinil—Infection—Epirubicin—uterine cancer	0.000455	0.00109	CcSEcCtD
Treprostinil—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000454	0.00884	CbGpPWpGaD
Treprostinil—Cough—Doxorubicin—uterine cancer	0.000453	0.00109	CcSEcCtD
Treprostinil—Shock—Epirubicin—uterine cancer	0.00045	0.00108	CcSEcCtD
Treprostinil—Thrombocytopenia—Epirubicin—uterine cancer	0.000448	0.00107	CcSEcCtD
Treprostinil—Tachycardia—Epirubicin—uterine cancer	0.000447	0.00107	CcSEcCtD
Treprostinil—Arthralgia—Doxorubicin—uterine cancer	0.000442	0.00106	CcSEcCtD
Treprostinil—Chest pain—Doxorubicin—uterine cancer	0.000442	0.00106	CcSEcCtD
Treprostinil—Myalgia—Doxorubicin—uterine cancer	0.000442	0.00106	CcSEcCtD
Treprostinil—Anxiety—Doxorubicin—uterine cancer	0.00044	0.00106	CcSEcCtD
Treprostinil—Discomfort—Doxorubicin—uterine cancer	0.000437	0.00105	CcSEcCtD
Treprostinil—Anorexia—Epirubicin—uterine cancer	0.000436	0.00105	CcSEcCtD
Treprostinil—PPARD—Gene Expression—CHD4—uterine cancer	0.000432	0.0084	CbGpPWpGaD
Treprostinil—Hypotension—Epirubicin—uterine cancer	0.000428	0.00103	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—CTNNB1—uterine cancer	0.000427	0.0083	CbGpPWpGaD
Treprostinil—Oedema—Doxorubicin—uterine cancer	0.000424	0.00102	CcSEcCtD
Treprostinil—Infection—Doxorubicin—uterine cancer	0.000421	0.00101	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000419	0.00816	CbGpPWpGaD
Treprostinil—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000417	0.001	CcSEcCtD
Treprostinil—Shock—Doxorubicin—uterine cancer	0.000417	0.000999	CcSEcCtD
Treprostinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000415	0.00809	CbGpPWpGaD
Treprostinil—Thrombocytopenia—Doxorubicin—uterine cancer	0.000415	0.000994	CcSEcCtD
Treprostinil—Insomnia—Epirubicin—uterine cancer	0.000414	0.000993	CcSEcCtD
Treprostinil—Tachycardia—Doxorubicin—uterine cancer	0.000413	0.000991	CcSEcCtD
Treprostinil—Paraesthesia—Epirubicin—uterine cancer	0.000411	0.000985	CcSEcCtD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00041	0.00798	CbGpPWpGaD
Treprostinil—Dyspnoea—Epirubicin—uterine cancer	0.000408	0.000978	CcSEcCtD
Treprostinil—Anorexia—Doxorubicin—uterine cancer	0.000404	0.000968	CcSEcCtD
Treprostinil—Dyspepsia—Epirubicin—uterine cancer	0.000403	0.000966	CcSEcCtD
Treprostinil—Decreased appetite—Epirubicin—uterine cancer	0.000398	0.000954	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—EP300—uterine cancer	0.000396	0.00772	CbGpPWpGaD
Treprostinil—Hypotension—Doxorubicin—uterine cancer	0.000396	0.000949	CcSEcCtD
Treprostinil—Fatigue—Epirubicin—uterine cancer	0.000395	0.000946	CcSEcCtD
Treprostinil—Pain—Epirubicin—uterine cancer	0.000391	0.000938	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000386	0.000925	CcSEcCtD
Treprostinil—Insomnia—Doxorubicin—uterine cancer	0.000383	0.000918	CcSEcCtD
Treprostinil—Paraesthesia—Doxorubicin—uterine cancer	0.00038	0.000912	CcSEcCtD
Treprostinil—Dyspnoea—Doxorubicin—uterine cancer	0.000378	0.000905	CcSEcCtD
Treprostinil—Feeling abnormal—Epirubicin—uterine cancer	0.000377	0.000904	CcSEcCtD
Treprostinil—Gastrointestinal pain—Epirubicin—uterine cancer	0.000374	0.000897	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—PGR—uterine cancer	0.000374	0.00728	CbGpPWpGaD
Treprostinil—Dyspepsia—Doxorubicin—uterine cancer	0.000373	0.000894	CcSEcCtD
Treprostinil—Decreased appetite—Doxorubicin—uterine cancer	0.000368	0.000883	CcSEcCtD
Treprostinil—Fatigue—Doxorubicin—uterine cancer	0.000365	0.000875	CcSEcCtD
Treprostinil—Pain—Doxorubicin—uterine cancer	0.000362	0.000868	CcSEcCtD
Treprostinil—Abdominal pain—Epirubicin—uterine cancer	0.000362	0.000868	CcSEcCtD
Treprostinil—Body temperature increased—Epirubicin—uterine cancer	0.000362	0.000868	CcSEcCtD
Treprostinil—PPARD—Gene Expression—SUZ12—uterine cancer	0.000362	0.00704	CbGpPWpGaD
Treprostinil—PTGIR—Thromboxane A2 receptor signaling—AKT1—uterine cancer	0.000353	0.00686	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NDUFB11—uterine cancer	0.000352	0.00685	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—SRD5A2—uterine cancer	0.000352	0.00685	CbGpPWpGaD
Treprostinil—PPARD—Adipogenesis—CTNNB1—uterine cancer	0.000351	0.00684	CbGpPWpGaD
Treprostinil—Feeling abnormal—Doxorubicin—uterine cancer	0.000349	0.000837	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—IRF1—uterine cancer	0.000349	0.00679	CbGpPWpGaD
Treprostinil—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000346	0.00083	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000342	0.00665	CbGpPWpGaD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000337	0.00656	CbGpPWpGaD
Treprostinil—PPARD—Ectoderm Differentiation—CTNNB1—uterine cancer	0.000335	0.00652	CbGpPWpGaD
Treprostinil—Body temperature increased—Doxorubicin—uterine cancer	0.000335	0.000803	CcSEcCtD
Treprostinil—Abdominal pain—Doxorubicin—uterine cancer	0.000335	0.000803	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—ESR2—uterine cancer	0.000329	0.00641	CbGpPWpGaD
Treprostinil—Asthenia—Epirubicin—uterine cancer	0.000328	0.000787	CcSEcCtD
Treprostinil—Pruritus—Epirubicin—uterine cancer	0.000324	0.000776	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000323	0.00628	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—IRF1—uterine cancer	0.000321	0.00625	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	0.000317	0.00618	CbGpPWpGaD
Treprostinil—Diarrhoea—Epirubicin—uterine cancer	0.000313	0.000751	CcSEcCtD
Treprostinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000306	0.00595	CbGpPWpGaD
Treprostinil—Asthenia—Doxorubicin—uterine cancer	0.000304	0.000729	CcSEcCtD
Treprostinil—Dizziness—Epirubicin—uterine cancer	0.000303	0.000726	CcSEcCtD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000302	0.00587	CbGpPWpGaD
Treprostinil—Pruritus—Doxorubicin—uterine cancer	0.0003	0.000718	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	0.000295	0.00574	CbGpPWpGaD
Treprostinil—Vomiting—Epirubicin—uterine cancer	0.000291	0.000698	CcSEcCtD
Treprostinil—Diarrhoea—Doxorubicin—uterine cancer	0.00029	0.000695	CcSEcCtD
Treprostinil—Rash—Epirubicin—uterine cancer	0.000289	0.000692	CcSEcCtD
Treprostinil—Dermatitis—Epirubicin—uterine cancer	0.000288	0.000691	CcSEcCtD
Treprostinil—Headache—Epirubicin—uterine cancer	0.000287	0.000688	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—uterine cancer	0.000284	0.00552	CbGpPWpGaD
Treprostinil—Dizziness—Doxorubicin—uterine cancer	0.00028	0.000671	CcSEcCtD
Treprostinil—Nausea—Epirubicin—uterine cancer	0.000272	0.000652	CcSEcCtD
Treprostinil—Vomiting—Doxorubicin—uterine cancer	0.000269	0.000646	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000268	0.00522	CbGpPWpGaD
Treprostinil—Rash—Doxorubicin—uterine cancer	0.000267	0.00064	CcSEcCtD
Treprostinil—Dermatitis—Doxorubicin—uterine cancer	0.000267	0.00064	CcSEcCtD
Treprostinil—Headache—Doxorubicin—uterine cancer	0.000265	0.000636	CcSEcCtD
Treprostinil—PPARD—Metabolism—AKR1B1—uterine cancer	0.000254	0.00495	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—STAR—uterine cancer	0.000254	0.00495	CbGpPWpGaD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	0.000252	0.0049	CbGpPWpGaD
Treprostinil—Nausea—Doxorubicin—uterine cancer	0.000252	0.000603	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000251	0.0049	CbGpPWpGaD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000248	0.00483	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—SMAD3—uterine cancer	0.000245	0.00477	CbGpPWpGaD
Treprostinil—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000236	0.0046	CbGpPWpGaD
Treprostinil—P2RY12—G alpha (i) signalling events—CXCL8—uterine cancer	0.000235	0.00457	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKR1B10—uterine cancer	0.000226	0.00441	CbGpPWpGaD
Treprostinil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000217	0.00423	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	0.000216	0.00421	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKR1B10—uterine cancer	0.000208	0.00406	CbGpPWpGaD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	0.0002	0.0039	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—ESR1—uterine cancer	0.0002	0.00389	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—POLD1—uterine cancer	0.0002	0.00389	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	0.00019	0.0037	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—RNF43—uterine cancer	0.000188	0.00365	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—AKR1C1—uterine cancer	0.000187	0.00363	CbGpPWpGaD
Treprostinil—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000187	0.00363	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—PGR—uterine cancer	0.00018	0.00351	CbGpPWpGaD
Treprostinil—P2RY12—GPCR ligand binding—CCL2—uterine cancer	0.00018	0.0035	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	0.000179	0.00348	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	0.000176	0.00344	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—RNF43—uterine cancer	0.000173	0.00336	CbGpPWpGaD
Treprostinil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000172	0.00334	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—INHBA—uterine cancer	0.000172	0.00334	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—EZH2—uterine cancer	0.000171	0.00333	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	0.000167	0.00324	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—RRM2—uterine cancer	0.000166	0.00324	CbGpPWpGaD
Treprostinil—PTGIR—GPCR ligand binding—CCL2—uterine cancer	0.000165	0.00322	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—DCN—uterine cancer	0.000162	0.00315	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000159	0.00309	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ESR2—uterine cancer	0.000159	0.00309	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—INHBA—uterine cancer	0.000158	0.00307	CbGpPWpGaD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	0.000156	0.00304	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKR1C1—uterine cancer	0.000154	0.00301	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP11A1—uterine cancer	0.000152	0.00296	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—AKR1C3—uterine cancer	0.000144	0.0028	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKR1C1—uterine cancer	0.000142	0.00277	CbGpPWpGaD
Treprostinil—P2RY12—GPCR ligand binding—CXCL8—uterine cancer	0.000142	0.00277	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	0.000132	0.00256	CbGpPWpGaD
Treprostinil—PTGIR—GPCR ligand binding—CXCL8—uterine cancer	0.000131	0.00255	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	0.00013	0.00253	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—CDKN2B—uterine cancer	0.000129	0.00251	CbGpPWpGaD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—AKT1—uterine cancer	0.000128	0.00249	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKR1C3—uterine cancer	0.000119	0.00232	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—SMAD3—uterine cancer	0.000118	0.00229	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PGR—uterine cancer	0.000116	0.00226	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000115	0.00224	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000115	0.00224	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—STK11—uterine cancer	0.000112	0.00218	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP19A1—uterine cancer	0.000112	0.00218	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—YWHAE—uterine cancer	0.000111	0.00215	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKR1C3—uterine cancer	0.000109	0.00213	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—EP300—uterine cancer	0.000109	0.00212	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PGR—uterine cancer	0.000107	0.00208	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FBXW7—uterine cancer	0.000106	0.00206	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.000105	0.00205	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—VEGFA—uterine cancer	0.000103	0.00201	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—NRAS—uterine cancer	0.000102	0.00198	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—YWHAE—uterine cancer	0.000102	0.00198	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—EP300—uterine cancer	0.0001	0.00195	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.0001	0.00195	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FBXW7—uterine cancer	9.75e-05	0.0019	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ESR1—uterine cancer	9.62e-05	0.00187	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—VEGFA—uterine cancer	9.5e-05	0.00185	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—NRAS—uterine cancer	9.38e-05	0.00183	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—STK11—uterine cancer	9.26e-05	0.0018	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—CCL2—uterine cancer	9.22e-05	0.0018	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—KRAS—uterine cancer	8.77e-05	0.00171	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SOCS3—uterine cancer	8.68e-05	0.00169	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—STK11—uterine cancer	8.53e-05	0.00166	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—CCL2—uterine cancer	8.49e-05	0.00165	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	8.43e-05	0.00164	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—MTHFR—uterine cancer	8.41e-05	0.00164	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN2B—uterine cancer	8.31e-05	0.00162	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—KRAS—uterine cancer	8.07e-05	0.00157	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IGF1R—uterine cancer	8.07e-05	0.00157	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—PIK3CA—uterine cancer	8.06e-05	0.00157	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—CXCL8—uterine cancer	8.03e-05	0.00156	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SOCS3—uterine cancer	7.98e-05	0.00155	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—TP53—uterine cancer	7.8e-05	0.00152	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN2B—uterine cancer	7.64e-05	0.00149	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SMAD3—uterine cancer	7.58e-05	0.00148	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—HRAS—uterine cancer	7.46e-05	0.00145	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IGF1R—uterine cancer	7.42e-05	0.00145	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—PIK3CA—uterine cancer	7.42e-05	0.00144	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.41e-05	0.00144	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—CXCL8—uterine cancer	7.39e-05	0.00144	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—CXCL8—uterine cancer	7.29e-05	0.00142	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FGFR2—uterine cancer	7.23e-05	0.00141	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—TP53—uterine cancer	7.18e-05	0.0014	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NDUFB11—uterine cancer	7.07e-05	0.00138	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SRD5A2—uterine cancer	7.07e-05	0.00138	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SMAD3—uterine cancer	6.98e-05	0.00136	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	6.87e-05	0.00134	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—HRAS—uterine cancer	6.86e-05	0.00134	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—CXCL8—uterine cancer	6.71e-05	0.00131	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FGFR2—uterine cancer	6.66e-05	0.0013	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—AKT1—uterine cancer	6.58e-05	0.00128	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	6.49e-05	0.00126	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ESR1—uterine cancer	6.19e-05	0.0012	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—AKT1—uterine cancer	6.06e-05	0.00118	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—NRAS—uterine cancer	5.85e-05	0.00114	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ESR1—uterine cancer	5.69e-05	0.00111	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CCL2—uterine cancer	5.45e-05	0.00106	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—NRAS—uterine cancer	5.38e-05	0.00105	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—STAR—uterine cancer	5.11e-05	0.000996	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKR1B1—uterine cancer	5.11e-05	0.000996	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—PIK3CA—uterine cancer	5.09e-05	0.000992	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.05e-05	0.000984	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—KRAS—uterine cancer	5.03e-05	0.00098	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CCL2—uterine cancer	5.01e-05	0.000976	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—PIK3CA—uterine cancer	4.69e-05	0.000913	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTEN—uterine cancer	4.68e-05	0.000911	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—KRAS—uterine cancer	4.63e-05	0.000902	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PIK3CA—uterine cancer	4.63e-05	0.000901	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ERBB2—uterine cancer	4.54e-05	0.000884	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—EP300—uterine cancer	4.46e-05	0.000869	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CXCL8—uterine cancer	4.31e-05	0.000839	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—HRAS—uterine cancer	4.28e-05	0.000833	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PIK3CA—uterine cancer	4.26e-05	0.000829	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1B—uterine cancer	4.21e-05	0.000819	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB2—uterine cancer	4.18e-05	0.000814	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—AKT1—uterine cancer	4.16e-05	0.00081	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—POLD1—uterine cancer	4.01e-05	0.000781	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CTNNB1—uterine cancer	3.97e-05	0.000774	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CXCL8—uterine cancer	3.96e-05	0.000772	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—HRAS—uterine cancer	3.94e-05	0.000767	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PTEN—uterine cancer	3.87e-05	0.000754	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1B—uterine cancer	3.87e-05	0.000754	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—AKT1—uterine cancer	3.83e-05	0.000746	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—AKT1—uterine cancer	3.78e-05	0.000736	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKR1C1—uterine cancer	3.75e-05	0.000731	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EP300—uterine cancer	3.69e-05	0.000719	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CTNNB1—uterine cancer	3.66e-05	0.000712	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PTEN—uterine cancer	3.56e-05	0.000694	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—VEGFA—uterine cancer	3.5e-05	0.000681	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—AKT1—uterine cancer	3.48e-05	0.000677	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—AKT1—uterine cancer	3.47e-05	0.000675	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NRAS—uterine cancer	3.46e-05	0.000673	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EP300—uterine cancer	3.4e-05	0.000662	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—RRM2—uterine cancer	3.35e-05	0.000651	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CA—uterine cancer	3.3e-05	0.000643	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—DCN—uterine cancer	3.25e-05	0.000632	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—VEGFA—uterine cancer	3.22e-05	0.000627	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NRAS—uterine cancer	3.18e-05	0.000619	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP11A1—uterine cancer	3.06e-05	0.000596	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KRAS—uterine cancer	2.97e-05	0.000579	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKR1C3—uterine cancer	2.89e-05	0.000563	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KRAS—uterine cancer	2.74e-05	0.000533	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CA—uterine cancer	2.73e-05	0.000532	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—AKT1—uterine cancer	2.7e-05	0.000525	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—uterine cancer	2.64e-05	0.000515	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HRAS—uterine cancer	2.53e-05	0.000492	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CA—uterine cancer	2.51e-05	0.00049	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—uterine cancer	2.43e-05	0.000474	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HRAS—uterine cancer	2.33e-05	0.000453	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—STK11—uterine cancer	2.25e-05	0.000438	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP19A1—uterine cancer	2.25e-05	0.000438	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKT1—uterine cancer	2.23e-05	0.000435	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.11e-05	0.000411	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKT1—uterine cancer	2.05e-05	0.0004	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.02e-05	0.000392	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MTHFR—uterine cancer	1.69e-05	0.000329	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.49e-05	0.00029	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTEN—uterine cancer	9.41e-06	0.000183	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—EP300—uterine cancer	8.97e-06	0.000175	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CA—uterine cancer	6.64e-06	0.000129	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKT1—uterine cancer	5.42e-06	0.000106	CbGpPWpGaD
